Mesenchymal stem cells were developed as a cell-based therapeutic in the 1990’s.The translation of culture expanded mesenchymal stem cells from a basic science focus into a modern therapeutic has taken 30 years.The c...Mesenchymal stem cells were developed as a cell-based therapeutic in the 1990’s.The translation of culture expanded mesenchymal stem cells from a basic science focus into a modern therapeutic has taken 30 years.The current state of the basic science information argues that mesenchymal stem cells may be curative for coronavirus disease 2019(COVID-19).Indeed,early small-scale clinical trials have shown positive results.The issue raised is how to assemble the resources to get this cell-based therapy approved for clinical use.The technology is complex,the COVID-19 viral infections are life threatening,the cost is high,but human life is precious.What will it take to perfect this potentially curative technology?展开更多
基金supported by the Virginia and David Baldwin Fund。
文摘Mesenchymal stem cells were developed as a cell-based therapeutic in the 1990’s.The translation of culture expanded mesenchymal stem cells from a basic science focus into a modern therapeutic has taken 30 years.The current state of the basic science information argues that mesenchymal stem cells may be curative for coronavirus disease 2019(COVID-19).Indeed,early small-scale clinical trials have shown positive results.The issue raised is how to assemble the resources to get this cell-based therapy approved for clinical use.The technology is complex,the COVID-19 viral infections are life threatening,the cost is high,but human life is precious.What will it take to perfect this potentially curative technology?
